INTRODUCTION
Over the past three decades, technological advances have transformed the conceptual framework of Alzheimer's disease (AD) . Post-mortem studies demonstrated a high degree of neuropathological heterogeneity in patients who received a clinical diagnosis of AD, emphasizing the need to develop reliable in vivo biomarkers for AD-related pathophysiology (Rabinovici et al., 2017) . Accordingly, the current research diagnostic criteria (Dubois et al., 2007 (Dubois et al., , 2010 Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011) recommend the biomarker-based in vivo demonstration of AD pathomechanistic alterations, i.e. brain overaccumulation of both brain amyloid-β (Aβ) (as indicated by low Aβ peptide [Aβ concentrations in the cerebrospinal fluid [CSF] ) and neurofibrillary tangles (as indicated by elevated CSF concentrations of hyperphosphorylated tau [p-tau] and total tau [t-tau] proteins). Furthermore, the growing need for early-stage clinical trials for disease-modifying therapies is fostering a progressive shift from a clinical toward a biological definition of AD, along its clinical continuum (Jack et al., 2018) . For the sake of stratifying individuals by AD pathomechanistic alterations, the "A/T/N" scheme, an agnostic conceptual framework focused on a biological definition of the pathophysiological continuum of AD, has been proposed. The A/T/N categorizes individuals by the presence/absence of core AD-related pathophysiological hallmarks (Aβ and tau proteinopathies plus neurodegeneration) (Jack et al., 2016a (Jack et al., , 2018 .
In the next years, the implementation of the current A/T/N scheme with additional pathophysiological process, including neuroinflammation, axonal damage, and synaptic dysfunction is expected to occur (Hampel et al., 2018b; Molinuevo et al., 2018) . The integration of the A/T/N system in clinical trials is expected to support time-sensitive pathway-based therapeutic approaches.
Ideally, all relevant pathophysiological mechanisms supporting AD should be integrated into a biomarker-guided stratification strategy to support the aggregation of patients from large-scale population studies into homogeneous "clusters" (i.e. strata of individuals with distinct biomarker profiles) independent of clinical phenotypes. This regrouping (i.e. stratification) strategy has the potential to establish subsets of individuals which share similar disease-related trajectories and drug-responses. In this context, one study predicted patient evolution based on clusters generated from both cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) data (Nettiksimmons et al., 2010) . Previous work clustered AD patients using, e.g., the CLustering In QUEst (CLIQUE) strategy (Gamberger et al., 2016a (Gamberger et al., , 2016b ) (not including dimensionality reduction and focused on patients with a very large number of attributes), hierarchical clustering (which provides a multiscale picture of clusters but no indication of which dimensionality to choose), or k-means clustering (which requires a priori determination of the number of clusters) for profiling AD patients, older adults in general (Escudero et al., 2012; Zemedikun et al., 2018) , or patients with other disorders, including aphasia (Hoffman et al., 2017) .
In this exploratory analysis, we sought to investigate whether different AD clinical syndromes may drop into different biomarker-driven clusters as well as whether different clinical syndromes may drop into the same biomarker-driven cluster.
In view of this objective, we recruited the entire continuum of the AD "construct" -from the asymptomatic cognitively normal preclinical stage , including subjective memory complainers (SMC), through mild cognitive impairment (MCI), all the way to clinically overt dementia. We employed a panel of validated and innovative CSF biomarkers, including (I) the traditional CSF core, feasible (Frank et al., 2003; Hampel et al., 2008) biomarkers to track AD pathophysiology -the forty-two-amino acid-long amyloid-β peptide (Aβ 1-42 ), t-tau, and tau hyperphosphorylated at threonine 181 (p-tau 181 ) proteins (Dubois et al., 2007 (Dubois et al., , 2010 (Dubois et al., , 2014 Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011; Jack et al., 2016a ) -and (II) two additional CSF candidate biomarkers: neurofilament light chain (NFL) (Lista et al., 2017 ) − a structural component of the neuroaxonal cytoskeleton − and YKL-40 (Baldacci et al., 2017b ) − a specific macrophage differentiation glycoprotein highly expressed in astrocytes. These are biomarkers of large-caliber myelinated axons disintegration and astrocytic activation, which are core mechanisms of neurodegeneration and neuroinflammation Baldacci et al., 2017a) , respectively.
We believe that asking this question may provide useful insights for next clinical trials investigating biomarker-guided molecular combination therapies for AD.
MATERIAL AND METHODS

Study participants
We conducted a multicenter cross-sectional study in a convenience sample (N=113) recruited in three independent academic memory clinics. Particularly, healthy controls (HC) (N=20), SMC (N=36), MCI (N=20), and AD dementia (ADD) (N=37) individuals were examined. Age, sex, and Mini-Mental State Examination (MMSE) were reported in Table 1 .
Specifically, 58 participants were recruited from the Institute for Memory and Alzheimer's Disease (Institut de la Mémoire et de la Maladie d'Alzheimer, IM2A) -a sub-cohort of the Alzheimer Precision Medicine Initiative Cohort Program (APMI-CP; available at https://www.apmiscience.com/) (Hampel et al., 2017; Hampel et al., 2018c; Hampel et al., 2019 ) -at the Pitié-Salpêtrière University Hospital (Paris, France), 42 from the German Center for Neurodegenerative Diseases (DZNE) (Rostock, Germany), and 13 from the Institute of Neuroscience and Physiology at Sahlgrenska University Hospital (Mölndal, Sweden). The recruitment center will be referred to as "site" in this paper.
The study complied with the tenets of the Declaration of Helsinki of 1975 and was approved by the local Ethical Committees at each participating university center. All participants or their representatives gave written informed consent for the use of their clinical data for research purposes.
Clinical diagnosis
The clinical diagnosis of ADD was performed according to the National Institute of
Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related
Disorders Association (NINCDS-ADRDA) consensus criteria (McKhann et al., 1984) and the clinical core of the current diagnostic criteria for the amnestic presentation of AD dementia (McKhann et al., 2011; Dubois et al., 2014) . N=37 patients with ADD were included. All participants had a diagnosis of typical ADD (i.e. hippocampal type).
The clinical diagnosis of MCI was based on the MCI core clinical criteria (Albert et al., 2011) . The group clinically defined as MCI included 20 participants. These individuals, predominantly amnestic type MCI, had a one-year clinical follow-up. Three of them converted to ADD within one year.
Thirty-six participants with SMC, available at the time of study execution, were recruited from the "INveStIGation of AlzHeimer's PredicTors in Subjective Memory Complainers" (INSIGHT-preAD) study, a French standardized large-scale, observational, mono-centric, academic, university-based cohort which is part of the APMI-CP (https://www.apmiscience.com/) (Hampel et al., 2017; Dubois et al., 2018; Hampel et al., 2018c; Hampel et al., 2019) at the time of the preparation of the manuscript. The status of SMC was confirmed as follows: (I) participants gave an affirmative answer ("YES") to both questions: "Are you complaining about your memory?" and "Is it a regular complaint that has lasted now more than 6 months?"; (II) participants presented intact cognitive functions based on MMSE score ≥ 27, Clinical Dementia Rating scale (CDR=0), and Free and Cued Selective Rating Test (FCSRT, total recall score ≥ 41) . Amyloid-positron emission tomography (PET) imaging investigation was performed at baseline visit, as mandatory study inclusion criterion. Ten SMC participants were amyloid-PET positive and 26 participants were amyloid-PET negative. Amyloid-PET imaging processing has been previously described Habert et al., 2018) .
Cognitively HC (N=20) were individuals who: (I) volunteered for lumbar puncture, (II) were free of neurological or psychiatric diseases, and (III) had a MMSE score between 27 and 30.
2.3. CSF sampling and immunoassays for CSF core biomarkers, NFL, and YKL-40
CSF withdrawn and pre-analytical procedures
CSF was taken in the morning through a standard lumbar puncture. All CSF samples used in the present study and deriving from the three different cohorts were collected in polypropylene tubes and processed as follows: centrifugation at 1,000 g for 10 minutes at the temperature of +4°C (IM2A, Pitié-Salpêtrière University Hospital, in Paris), 1,500 g for 10 minutes at the temperature of +4°C (samples collected at the Department of Psychosomatic Medicine inside the University of Rostock), 1,800 g for 10 minutes at the temperature of +4°C (samples collected at the Clinical Neurochemistry Laboratory in Mölndal). The obtained supernatant was collected, homogenized, and aliquoted into multiple 0.5 mL cryovialsterilized tubes, and finally stored at -80°C within 1 hour from collection and until biochemical assessment. (Mattsson et al., 2011) and the Global Biomarker Standardization Consortium (Carrillo et al., 2013) . The threshold cut-off values for identifying pathologic concentrations of the core biomarkers were different across laboratories i.e.: at the IM2A in Paris, Aβ 1-42 < 500 pg/mL, t-tau > 450 pg/mL, p-tau 181 > 60 pg/mL; at DZNE in Rostock, Aβ 1-42 < 567 pg/mL, t-tau > 512 pg/mL, p-tau 181 > 66 pg/mL (for the CSF samples assessed before June 2012) and Aβ 1-42 < 450 pg/mL, t-tau > 450 pg/mL, p-tau 181 > 62 pg/mL (for the CSF samples assessed after June 2012); at Clinical Neurochemistry Laboratory in Mölndal, Aβ 1-42 < 550 pg/mL, t-tau > 400 pg/mL, p-tau 181 > 80 pg/mL.
Immunoassays for the assessment of CSF core biomarkers of AD
Immunoassays for the assessment of CSF biomarkers NFL and YKL-40
CSF NFL and YKL-40 were analyzed at the Clinical Neurochemistry Laboratory at the Sahlgrenska University Hospital in Mölndal, Sweden. In particular, CSF NFL protein concentrations were quantified using a sensitive sandwich ELISA method (NF-light ELISA kit; UmanDiagnostics AB, Umeå, Sweden), according to the recommendations provided by the manufacturer. The lower limit of quantification (LLOQ) for this assay was 50 ng/L. CSF YKL-40 protein concentrations were quantified using a commercially available ELISA kit (R&D Systems, Minneapolis, MN, US), according to manufacturer instructions. The LLOQ for this assay was 60 pg/mL. All patient samples showed values above the in-house LLOQ.
Intra-assay coefficients of variation were below 10%. The measurements of each biomarker were performed in one round of experiments, using the same batch of reagents, by boardcertified laboratory technicians who were blinded to the clinical data.
Statistical analysis
Our data allowed us to represent every participant as a "point" in a five-dimensional space,
where the five coordinates are the five CSF biomarkers under investigation (Aβ 1-42, t-tau, ptau 181, NFL, YKL-40). In accordance with our hypothesis that the embedding of individuals in this biomarker-based space could be able to reveal novel, unknown associations as well as possibly categories of individuals -i.e. clusters -we proceeded as follows.
As a first step, in order to eliminate age-and sex-related confounds, both variables were simultaneously regressed-out of all biomarker values using a quadratic regression model which also included age-sex interaction. Then, this five-dimensional space of adjusted (for age, sex, and their interaction) biomarker values was fed into t-Distributed Stochastic Neighbor Embedding (t-SNE) to reduce dimensionality and, successively, into density -based clustering to formally identify clusters of arbitrary shape/different densities without imposing prior constraints on the number of clusters. t-SNE is a non-linear dimensionality reduction technique well-suited for embedding high-dimensional data for visualization in a lowdimensional space of two or three dimensions. Specifically, in t-SNE a probability distribution over pairs of high-dimensional objects is constructed so that similar objects have a high probability of being picked while minimizing the probability of picking dissimilar points. Successively, another probability distribution is designed over the points in a lowerdimensional map, and finally the Kullback-Leibler divergence between the two distributions is minimized with respect to where the points are located in the map. This allows an efficient and high-performing dimensionality reduction problem which optimally preserves highdimensional relationship between data points (Maaten, 2014 (Maaten, , 2009 Maaten and Hinton, 2008;  van der Maaten and Hinton, 2012) . Then, density-based clustering (Density-Based Spatial
Clustering of Applications with Noise, DBSCAN) (Patwary et al., 2012; Tran et al., 2013) can be applied to the low-dimensional representation to automatically identify clusters. It groups closely packed points (i.e. points with a high number of close neighbors) and marks points low-density regions as outliers (i.e. noise). Briefly, when a point is found to be a dense part of a cluster, its ε-neighborhood is also considered to belong to the same cluster and all corresponding points are added, as well as their own ε-neighborhood when they are also dense, continuing until the density-connected cluster is complete. Successively, a point which has not previously been visited is retrieved and processed the same way -this can lead to the discovery of either noise or of a further cluster. Both t-SNE and DBSCAN can be used with any distance function and do not require initial, arbitrary determination of the number of clusters. In terms of validation, while some methods have been proposed to test the generalizability of unsupervised clustering methods (Tibshirani and Walther, 2005) , it should be noted that the DBSCAN approach seeks to explore the data for partitions with high density areas of points (clusters i.e. clusters which, importantly, are not necessarily globular) separated by low density areas, possibly containing noise objects. Dealing with noise objects correctly in a validation approach is a challenge that makes the definition of external or even cross-validated methods arduous, and no method has yet been proposed for this particular case. Also, standard internal validity metrics commonly applied in unsupervised clustering applications (like, e.g. silhouette analysis) fail for arbitrarily shaped, non-convex clusters and, again, are not defined for noise objects. For the purpose of this revision, we have implemented a recently presented method for density-based, arbitrarily shaped clusters (Moulavi et al., 2014) which assesses clustering quality based on the relative density connection between pairs of objects and is based on a new kernel density function. After cluster identification, in order to explore cluster profiles and how different we were from each other, we employed several strategies: first, the average minimum Manhattan Distance between every pair of clusters was calculated. Also, biomarker values were compared across clusters using Kruskal-Wallis tests, and when a significant (P<0.05) effect of group (i.e. cluster) was found, post-hoc tests were conducted in order to identify the main drivers of this effect (2-sided tests adjusted for multiple comparisons across pairs of clusters). Additionally, for each biomarker, the overall dataset was divided in quintiles (see Table 2A for quintile boundaries) in order to observe to which quintile the median value of each biomarker in each cluster belonged. Using quintiles has the advantage of defining robust ranking intervals, 
RESULTS
Demographic and clinical data of the individuals stratified by clinical diagnosis are reported in Table 1 .
We found 5 distinct clusters of individuals (sizes: N=38, N=16, N=24, N=14, N=21). The low dimensional embedding, which provides an easily readable 2D representation of the clusters we found, is shown in Fig. 2 . We obtained a density-based cluster validation index of 0.67, indicating good quality clustering.
Cross-tabulation based on cluster assignment and clinical categorization -i.e. HC, SMC, MCI, and ADD -is shown in Table 3 and the distribution of each biomarker across clusters is shown in Fig. 3 . Particularly, Finally, computing biomarker quintiles across the whole population and allocating cluster medians for each biomarker to each quintile resulted in the cluster profiles shown in Table   2C .
It should be noted that, while Table 5 is based on simply comparing medians (while the multivariate cluster formation process is based on matching multivariate probability distributions), along with Tables 2C and 2B, it can provide an idea of the strongest drivers of the cluster formation process. One could e.g. examine in how many biomarkers a given pairwise comparison is statistically significant or, conversely, in how many pairwise comparisons a given biomarker is significantly different between pairs of clusters (see Discussion). For example, the separations of Clusters 2 versus 3 (which corresponds to the highest distance between clusters; Table 2B ) and 3 versus 5 (which corresponds to the second-highest distance between clusters; Table 2B ) appear to be a result of several biomarkers in conjunction -possibly mainly driven by YKL-40 and t-tau in the first case and by YKL-40 in the second case. Also, median biomarker values are not statistically different between Clusters 2 versus 5 and 4 versus 5 (which corresponds to the lowest distance between clusters; Table 2B ). As mentioned above, this is not a discrepancy since the cluster forming process is based on the whole biomarker distribution as opposed to median values only. Also, a weak effect is noted in YKL-40 and NFL in comparing Cluster 3 versus Cluster 5. In terms of cluster profiles within the overall population, from Table 2C one can infer that, for example, Cluster 3 is characterized by a much higher (with respect to the whole population median) YKL-40 concentration, while Cluster 2 is characterized by lower (with respect to the whole population median) NFL, t-tau, and p-tau 181 concentrations, higher Aβ 1-42 concentration, and a much lower (with respect to the whole population median) YKL-40 concentration. By the same token and under the same approximations, one could infer that, overall, YKL-40 is the main driver of division, followed by t-tau, p-tau 181 , and NFL that contributes very little to cluster separation. Aβ 1-42 does not significantly contribute to cluster separation.
Description of clusters
Cluster 1 was the largest (N=38) and consisted of MCI (23.7%), SMC (26.3%), ADD (42.7%) participants, as well as of a small portion of HC (only 7.9%) participants. This cluster included a single MCI subject that converted to dementia at follow-up. CSF t-tau and p-tau 181 median concentrations were in the 4 th quintile (Table 2C ). These individuals showed significantly higher CSF concentrations of YKL-40 compared with those of Clusters 2 and 5.
CSF t-tau and p-tau 181 concentrations were significantly higher than those of Cluster 2 ( Fig. 3 and Table 5 ).
Cluster 2 (N=16) included ADD (31.3%), SMC (25.0%), MCI (25.0%), and HC (18.8%) participants. Only one subject, within the MCI group, converted to dementia at follow-up.
CSF YKL-40 median concentrations were in the bottom quintile and CSF NFL, t-tau, and ptau 181 were in the 2 nd quintile. On the contrary, the median concentrations of CSF Aβ 1-42 were in the 4 th quintile (Table 2C) . CSF YKL-40 concentrations were significantly lower than those of Clusters 1, 3, and 4. CSF t-tau and p-tau 181 concentrations were significantly lower than those of Clusters 1 and 3. CSF NFL concentrations were significantly lower than of those of Cluster 3 ( Fig. 3 and Table 5 ).
Cluster 3 (N=24) was represented by SMC (45.8%), ADD (29.2%), MCI (16.7%), and HC (8.3%) participants. These individuals showed the highest CSF YKL-40 concentrations compared with those of all other clusters ( Fig. 3 and Table 5 ) with a median concentration falling in the top quintile. CSF t-tau and p-tau 181 were in the 4 th quintile (Table 2C) . CSF concentrations of t-tau and p-tau 181 were significantly higher than those of Clusters 2 and 5.
CSF NFL concentrations were significantly higher compared with those of Cluster 2 ( Fig. 3 and Table 5 ).
Cluster 4 was the smallest one (N=14) and consisted of HC (35.7%), ADD (28.6%), MCI (14.3%), and SMC (21.4%) participants. One MCI subject converted to dementia at followup. CSF NFL median concentrations were in the 2 nd quintile ( Table 2C ). CSF YKL-40
concentrations were significantly higher than those of Cluster 2 and significantly lower than Cluster 3. CSF t-tau and p-tau 181 concentrations were significantly lower than those of Cluster 3 ( Fig. 3 and Table 5 ).
Cluster 5 (N=21) included SMC (38.1%), HC (33.3%), ADD (23.8%), and MCI (4.8%)
participants. CSF YKL-40 and t-tau median concentrations were in the 2 nd quintile whereas the median concentrations of CSF Aβ 1-42 were in the 4 th quintile (Table 2C) . CSF YKL-40
concentrations were significantly lower compared with those of Clusters 1 and 3. CSF t-tau and p-tau 181 concentrations were significantly lower than those of Cluster 3 ( Fig. 3 and Table   5 ).
DISCUSSION
In this clustering investigation, we asked the question of how many pathophysiological profiles may underlie the clinical progression of the typical (hippocampal type) AD phenotype (that encompasses syndromic diagnoses ranging from SMC to MCI to overt dementia) and asymptomatic individuals. To this end, we compared participant groups, generated via biostatistical clustering analysis, to groups obtained using a traditional diagnostic categorization based on currently available clinical diagnostic criteria. Importantly, in our approach, the number of clusters is not imposed a priori but, rather, determined automatically by optimality criteria. We explored the possibility of deriving a meaningful stratification of individuals distributed along the broad biological and clinical spectrum of AD Aisen et al., 2017) Relatedly, we did not find a biomarker-based cluster that uniquely corresponded to the clinical AD diagnosis. This is not unexpected, as it would only occur if this clinical diagnosis was homogeneous in terms of biomarker profiles. However, it is interesting to note that cluster 1 contains 42.3% of all AD patients, and that AD patients constitute 42.1% of the whole cluster count. This lends further support to the complex interplay and only partial overlap between clinical and biomarker-driven categories.
Cluster 3 was the furthest/most distant (Table 2B ) from the majority of other clusters (2, 4, and 5) but not from Cluster 1. Cluster 1 and Cluster 3 show a biomarker profile linked to neuronal dystrophy and loss, i.e. neurodegeneration (t-tau) and tau-mediated brain proteinopathy (p-tau 181 ) (and, additionally, in the case of Cluster 3), which do not entirely correspond to the predefined AD-related pathophysiological core ( Sperling et al., 2011; Dubois et al., 2014; Jack et al., 2016b Jack et al., , 2018 . These two clusters were mostly represented by ADD patients (Cluster 1) and SMC individuals (Cluster 3). Since CSF YKL-40 concentrations in Cluster 3 are significantly higher than those of Cluster 1, one could argue that an association between neurodegeneration, neurofibrillary deposition, and neuroinflammatory mechanisms may exist in cognitively normal subjects at risk for ADD (Baldacci et al., 2017a) .
Clusters 2, 4, and 5 were close to each other and presented average or lower median concentrations of biomarkers charting axonal damage and neurodegeneration -namely NFL and t-tau, of tau-mediated brain proteinopathy (p-tau 181 ) -and neuroinflammation (YKL-40) compared with those found in Clusters 1 and 3.
Moreover, Cluster 2 was the most distant from Clusters 1 and 3, which in turn showed the highest median concentrations of biomarkers of neurodegeneration and neuroinflammation.
Therefore, in spite of including a large share of ADD patients, Cluster 1 and Cluster 2 present different biomarker profiles, particularly with reference to the level of cerebral amyloidosis.
In addition, Cluster 2 showed, along with Cluster 5, higher median concentrations of Aβ 1-42 compared to all other clusters. The same clusters were characterized by a high degree of clinical heterogeneity, especially Cluster 2 which, however, is the second out of five for prevalence of ADD. It is important to note that the high-dimensional feature reduction and aggregation (i.e. clustering) approach we employed in this paper is able to deal with partial redundancies while still extracting additional information from multiple variables which exhibit collinearities. In line with the above, it is also important to note that partially collinear biomarkers do not necessarily imply a representation of the same pathomechanistic alteration. For example, in spite of p-tau and t-tau stemming from a common precursor, p-tau has been demonstrated to reflect neurofibrillary pathology while t-tau is an established marker of axonal damage and neuronal injury (Jack et al., 2018) . Indeed, an agnostic hypothesis-independent biomarkerdriven classification system (the A/T/N scheme) has been proposed to stratify individuals according to core AD-related pathological and pathophysiological hallmarks (brain overaccumulation of both Aβ and tau proteins aggregates, and neurodegeneration) (Jack et al., 2018) . In the currently available research diagnostic criteria as well as in the A/T/N scheme, CSF t-tau and p-tau 181 play a different role. Despite the fact that NFL represents a marker of axonal damage, similarly to t-tau, the former is more tightly related to the damage of largecaliber fiber axons (Shahim et al., 2016 (Shahim et al., , 2018 Jack et al., 2018) .
In summary, we found that our biomarker-guided clustering approach generates a set of specific clusters not significantly bound to original distinct clinically phenotyped diagnostic groups. Specifically, none of the clusters appears homogeneous enough to be translated into predefined clinical categories that can be considered specific of AD pathophysiology. Instead, each cluster includes all phenotypical groups. Interestingly, CSF Aβ 1-42 concentrations are less likely to have contributed to the process of cluster segregation. A potential explanation for this finding could be that Aβ 1-42 peptide modifications appear several years before symptoms onset and are perhaps not linearly associated with the progressions of neurodegeneration and cognitive decline (Sperling et al., 2011; Jack et al., 2013) . In contrast, all other biomarkers significantly contribute to separating clusters. In this regard, previous studies reported that all these biomarkers are positively correlated and associated with worsening of cognitive performance (Mattsson et al., 2016; Hampel et al., 2018d) . This finding allows us to hypothesize that the individuals included in Cluster 3 -i.e. those with the highest median YKL-40 concentration in CSF -may benefit from participating in targeted clinical trials using compounds acting against neuroinflammation. Moreover, our clusters do not show a significant "Site x Cluster" interaction and are generated after correction of biomarker values for age, sex, and their interaction, thus ensuring that our model is biologically robust to the impact of ageing and sexual dimorphism on AD-related pathophysiological mechanisms Ferretti et al., 2018; Hampel et al., 2018f) .
Unsupervised clustering strategies are ideal for identifying multivariate, non-linear associations between individuals which can be described or characterized by a large number of variables -e.g. biomarkers and clinical outcomes -by dealing with a n-dimensional space which cannot be treated appropriately through intuition or classical linear methods.
Particularly, these algorithms search for clusters by simultaneously taking all variables into account, regardless of their nature. The similarity metric employed can also be varied in case there is a strong hypothesis about the nature of the association between biomarkers. By Under the hypotheses that the input data contains all main information potentially driving the evolution of the disease, these findings might support the discovery and development of targeted and individualized therapies with proven disease-modifying effects, consistent with the standardized stepwise procedure of proof-of-pharmacology (Hampel et al., 2018a; Hampel et al., 2018g) . Thus, it would be possible to treat individuals at asymptomatic preclinical stages of the disease, when the imbalance of homeostatic dynamics is still potentially restorable and the functionality of brain networks can be preserved. This innovation, applied in drug research and development programs as well as in clinical practice, is in line with the precision pharmacology (Hampel et al., 2018e) and precision medicine paradigms (Hampel et al., , 2017 Hampel et al., 2018c; Hampel et al., 2019) . In this context, we anticipate that unsupervised methods -complemented by integrative disease modeling (Younesi and Hofmann-Apitius, 2013; Baldacci et al., 2016 Baldacci et al., , 2018 Hampel et al., 2017 ) -will accelerate and optimize clinical trial development for individualized treatments through the implementation of biomarker matrices serving for different contexts-of-use, namely risk prediction, early stratification and early detection and diagnosis, treatment efficacy and safety monitoring, and prognostic evaluation.
In follow-up studies, we plan to further expand the panel of pathophysiological biomarkers to establish a stratification algorithm which could include biomarkers of synaptic damage, such as neurogranin and alpha-synuclein .
Moreover, we also aim at including a core blood-based biomarker panel in order to take optimal advantage of the broad accessibility of blood-plasma-based analyses to screen international large-scale cohorts of asymptomatic individuals at risk (Hampel et al., 2018b; Hampel et al., 2018g) . This is of great importance for future translation of these classification, diagnostic, and early detection approaches into worldwide primary clinical practice.
Our explorative pilot study presents some caveats. First, our follow-up data is restricted to SMC and MCI participants, hence hampering the characterization of the cluster-wise subject- se, indicate instability of the clustering procedure. In this context, it is important to note that one of the overall aims of our paper is to demonstrate how the same clinical syndrome may be allocated to different biomarker-driven clusters as well as that different clinical syndromes may drop in the same biomarker-driven cluster. Also, given the partial collinearity of the biomarkers which is, however, possibly associated with different biological underpinnings, and the limited sample size, we hypothesized that a highly nonlinear and state of the art dimension reduction algorithm such as tSNE could allow better data separation and hence cluster identification as compared to running a clustering algorithm on the 5-dimensional data directly.
Our multicenter cohort is clinically heterogeneous -i.e. it includes individuals ranging from the status of SMC to overt ADD -and, although data were corrected for age using nonlinear regression, residual differences in terms of e.g. age may still affect the corrected concentrations of CSF biomarkers (Jack et al., 2016b) . In addition, our study did not use MRI or amyloid-PET imaging data, which, however, could be seamlessly included to enhance our or other clustering strategies, as previously reported (Ten Kate et al., 2018; Young et al., 2018) .
In conclusion, we found: (I) a set of biologically defined clusters not significantly linked to the clinical diagnosis, (II) that Aβ 1-42 is less likely to have contributed to the cluster segregation, and (III) that all other biomarkers, especially YKL-40, significantly contribute to separating clusters. We believe that this stratification approach, based on state-of-the-art biomarker-guided clustering algorithms, should not replace but, rather, complement, optimize, and enrich the traditional diagnostic approaches in neurology to design treatments tailored to the individual biological-clinical profile (Hampel et al., , 2017 Hampel et al., 2018c Hampel et al., 2019) . The integration of clinical data with biological comprehensive information may represent the crucial step forward to the development of an accurate biomarker-guided stratification framework, which has the potential to inform and innovate traditional diagnostic work-ups as well as treatment selection strategies for next-generation clinical trials. Abbreviations: Aβ 1-42 = forty-two-amino acid-long amyloid-β peptide; NFL = neurofilament light chain protein; p-tau 181 = tau hyperphosphorylated at threonine 181; t-tau = total tau protein. Abbreviations: ADD = Alzheimer's disease dementia; C1 = Cluster 1; C2 = Cluster 2; C3 = Cluster 3; C4 = Cluster 4; C5 = Cluster 5; CSF = cerebrospinal fluid; HC = healthy controls; MCI = mild cognitive impairment; SMC = subjective memory complainers. Notes: Numbers denote mean ± standard deviation for CSF biomarkers. Abbreviations: Aβ 1-42 = forty-two-amino acid-long amyloid-β peptide; CSF = cerebrospinal fluid; NFL = neurofilament light chain protein; p-tau 181 = tau hyperphosphorylated at threonine 181; t-tau = total tau protein. Notes: Only significant (<0.05) P values are shown. P values which are also significant after correction for multiple comparisons are shown in bold.
TABLES
Abbreviations: Aβ 1-42 = forty-two-amino acid-long amyloid-β peptide; C1 = Cluster 1; C2 = Cluster 2; C3 = Cluster 3; C4 = Cluster 4; C5 = Cluster 5; NFL = neurofilament light chain protein; ns. = non-significant; ptau 181 = tau hyperphosphorylated at threonine 181; t-tau = total tau protein.
HIGHLIGHTS
Our study used state-of-the-art biostatistical unsupervised clustering methods
We showed the existence of 5 biologically determined clusters of individuals Two clusters showed biomarker profiles linked to neurodegenerative processes One cluster was characterized by the neuroinflammation biomarker YKL-40
Biologically determined categories enhance guidance in predicting disease evolution
